Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancer

Next Previous
Trial Profile

Research on Liquid Biopsy in Patients with Gastrointestinal and Abdominal Malignancies, Including Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Futibatinib (Primary)
  • Indications Advanced breast cancer; Anal cancer; Appendiceal cancer; Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Head and neck cancer; Intestinal cancer; Liver cancer; Neuroendocrine carcinoma; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Pharmacodynamics
  • Acronyms GOZILA

Most Recent Events

  • 20 Jan 2024 Results of substudy from GOZILA , analyzing Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer, presented at the 2024 Gastrointestinal Cancers Symposium
  • 20 Jan 2024 Results of pooled analysis from pooled analysis of SCRUM-Japan studies, analyzing Efficacy of biomarker-matched therapy in advanced gastrointestinal cancers, presented at the 2024 Gastrointestinal Cancers Symposium
  • 31 May 2023 According to Guardant Health media release, data from this study will be presented at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top